Products - Bladder cancer | Topic | NICE

Showing 10 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
15 April 2026
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 November 2026
Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 February 2027
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bladder cancer: diagnosis and management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC